Berndt Modig is listed as an executive officer and director on 2 SEC Form D filings by 2 issuers between Dec 2014 and Jun 2019: Prosensa Holding N.V. (Leiden, Netherlands (as filed: P7) — biotechnology — 2014; $50.5M reported sold to 1 investors) and Kiadis Pharma N.V. (Amsterdam, Netherlands (as filed: P7) — biotechnology — 2019; $18.4M reported sold to 25 investors).
What this means 2 separate companies raised money with this person listed as executive officer and director, over about 5 years. Across those companies the filings report $68.8M sold in total.
Listed alongside Martijn Kleijwegt (2 shared filings), Annalisa Jenkins (1 shared filing), Arthur Lahr (1 shared filing), Daan Ellens (1 shared filing), David Mott (1 shared filing) and 13 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Berndt. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 2 public filings for Berndt Modig and found 2 differences: Form D filed 21 days after the first sale; Same name, different state: "Berndt A. Modig" (V8) is a separate record.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.